6-Thioguanine: A drug with unrealized potential for cancer therapy

Oncologist

Volumn 19, Issue 7, 2014, Pages 760-765

  Munshi, Pashna N ^a   Lubin, Martin ^c   Bertino, Joseph R ^b  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

6 thioguanine; Chemotherapy; Denovo purine synthesis; Folate antagonists

Indexed keywords

5' METHYLTHIOADENOSINE; 5' METHYLTHIOADENOSINE PHOSPHORYLASE; ADENINE PHOSPHORIBOSYLTRANSFERASE; AZASERINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MERCAPTOPURINE; METHOTREXATE; PHOSPHORIBOSYL PYROPHOSPHATE; PREDNISONE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG METABOLISM; GENE DELETION; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOHISTOCHEMISTRY; MISMATCH REPAIR; NEOPLASM; PRIORITY JOURNAL; PROSTATE CARCINOMA; PURINE SYNTHESIS; SOLID TUMOR; ANIMAL; NEOPLASMS;

ANIMALS; HUMANS; NEOPLASMS; THIOGUANINE;

EID: 84903607739     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0178     Document Type: Article

References (53)

1. Burchenal JH, Murphy ML, Ellison RR et al. Clinical evaluationofanewantimetabolite,6-mercaptopurine, in the treatment of acute leukemia and allied diseases. Blood 1953;8:965-999.
2. Stork LC, Matloub Y, Broxson E et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standardrisk acute lymphoblastic leukemia: Report of the Children's Oncology Group CCG-1952 clinical trial. Blood 2010;115:2740-2748.
3. Coulthard SA, Redfern CP, Vikingsson S et al. Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers. Mol Cancer Ther 2011;10:495-504.
4. Hitchings GH, Elion GB. The chemistry and biochemistry of purine analogs. Ann N Y Acad Sci 1954;60:195-199.
5. Maybaum J, Hink LA, Roethel WM et al. Dissimilar actions of 6-mercaptopurine and 6-thioguanine in Chinese hamster ovary cells. Biochem Pharmacol 1985;34:3677-3682.
6. Nelson JA, Carpenter JW, Rose LM et al. Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res 1975;35: 2872-2878.
7. Morgan CJ, Chawdry RN, Smith AR et al. 6-Thioguanine-induced growth arrest in 6-mercaptopurine-resistant human leukemia cells. Cancer Res 1994;54:5387-5393.
8. Coulthard S, Hogarth L. The thiopurines: An update. Invest New Drugs 2005;23:523-532.
9. Karran P. Thiopurines, DNA damage, DNA repair andtherapy-related cancer. BrMedBull 2006;79-80: 153-170.
10. Henderson JF, Junga IG. Potentiation of carcinostasis by combinations of thioguanine and 6-mercaptopurine. Biochem Pharmacol 1960;5: 167-168.
11. Lepage GA, Jones M. Further studies on the mechanism of action of 6-thioguanine. Cancer Res 1961;21:1590-1594.
12. LePage GA, Whitecar JP Jr. Pharmacology of 6-thioguanine in man. Cancer Res 1971;31:1627-1631.
13. Kovach JS, Rubin J, Creagan ET et al. Phase I trial of parenteral 6-thioguanine given on 5 consecutive days. Cancer Res 1986;46:5959-5962.
14. Britell JC, Moertel CG, Kvols LK et al. Phase II trial of iv 6-thioguanine in advanced colorectal carcinoma. Cancer Treat Rep 1981;65:909-910.
15. Presant CA, Denes AE, Liu C et al. Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine. Cancer 1984;53:2610-2614.
16. Ajani JA, Pazdur R, Winn RJ et al. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs 1991;9:257-259.
17. Ajani JA, Pazdur R, Winn RJ et al. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs 1991;9:369-371.
18. Kruter F, EisenbergerM, Sinibaldi Vet al. Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 1992;10:89-91.
19. Vokes EE, Lyss AP, Herndon JE II et al. Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the Cancer and Leukemia Group B. Ann Oncol 1992;3:727-732.
20. Williamson SK, Crowley J, Livingston RB et al. Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study. Invest New Drugs 1993;11:81-83.
21. Witte RS, Elson P, Stewart JA et al. A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer. Urol Oncol 1996;2:96-98.
22. Pandya KJ, Tormey DC, Davis TE et al. Phase II trial of 6-thioguanine in metastatic breast cancer. Cancer Treat Rep 1980;64:191-192.
23. Ingle JN, Twito DI, Suman VJ et al. Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancer. Am J Clin Oncol 1997;20:69-72.
24. Kyritsis AP, Yung WK, Jaeckle KA et al. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery 1996;39:921-926.
25. Heath JA, Turner CD, Poussaint TY et al. Chemotherapy for progressive low-grade gliomas in children older than ten years: The Dana-Farber experience. Pediatr Hematol Oncol 2003;20:497-504.
26. Carbone PP, Frei E III, Owens AH Jr. et al. 6-Thioguanine (NSC-752)-1 therapy in patients with multiple myeloma. Cancer Chemotherapy Rep 1964;36:59-62.
27. Edelstein MB, Crowley JJ, Valeriote FA et al. A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs 1990; 8(suppl 1):S83-S86.
28. Sullivan MP, Boyett J, Pullen J et al. Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer 1985;55:323-336.
29. Bertino JR, Lubin M, Johnson-Farley N et al. Lack of expression of MTAP in uncommon T-cell lymphomas. Clin Lymphoma Myeloma Leuk 2012; 12:306-309.
30. Marcé S, Balagué O, Colomo L et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: Implications for a potential targeted therapy. Clin Cancer Res 2006;12:3754-3761.
31. Bertino JR, Waud WR, Parker WB et al. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies. Cancer Biol Ther 2011;11:627-632.
32. Illei PB, Rusch VW, Zakowski MF et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesothelioma. Clin Can Res 2003;9:2108-2113.
33. Hustinx SR, Hruban RH, Leoni LM et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: A potential new target for therapy. Cancer Biol Ther 2005;4:83-86.
34. Nobori T, Szinai I, Amox D et al. Methylthioadenosine phosphorylase deficiency in human nonsmall cell lung cancers. Cancer Res 1993;53: 1098-1101.
35. García-Castellano JM, Villanueva A, Healey JH et al. Methylthioadenosine phosphorylase gene deletions arecommon in osteosarcoma. Clin Cancer Res 2002;8:782-787.
36. Nobori T, Karras JG, Della Ragione F et al. Absence of methylthioadenosine phosphorylase in human gliomas. Cancer Res 1991;51:3193-3197.
37. Huang HY, Li SH, Yu SC et al. Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors. Clin Cancer Res 2009;15:6963-6972.
38. Batova A, Diccianni MB, Nobori T et al. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: Strategies for enzyme-targeted therapy. Blood 1996;88:3083-3090.
39. Mirebeau D, Acquaviva C, Suciu S et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 2006;91: 881-885.
40. Traweek ST, Riscoe MK, Ferro AJ et al. Methylthioadenosine phosphorylase deficiency in acute leukemia: Pathologic, cytogenetic, and clinical features. Blood 1988;71:1568-1573.
41. Hori Y, Hori H, Yamada Y et al. The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. Int J Cancer 1998;75:51-56.
42. Varshavsky A. Targeting the absence: Homozygous DNA deletions as immutable signposts for cancer therapy. Proc Natl Acad Sci USA 2007;104: 14935-14940.
43. Savarese TM, Chu SH, Chu MY et al. 59-Deoxy-59-methylthioadenosine phosphorylase-III. Role of the enzyme in the metabolism and action of 59-halogenated adenosine analogs. Biochem Pharmacol 1985;34:361-367.
44. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: A novel strategy. PLoS One 2009;4:e5735.
45. Collins CC, Volik SV, Lapuk AV et al. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther 2012;11:775-786.
46. Tang B, Testa JR, Kruger WD. Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss ofMTAPin tumor cells. Cancer Biol Ther 2012;13:1082-1090.
47. Batova A, Cottam H, Yu J et al. EFA (9-beta-Derythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood 2006;107:898-903.
48. KindlerHL, BurrisHAIII, SandlerAB et al. Aphase IImulticenterstudyof L-alanosine, apotentinhibitorof adenine biosynthesis, in patients withMTAP-deficient cancer. Invest New Drugs 2009;27:75-81.
49. Sartorelli AC, Lepage GA. Inhibition of ascites cell growth by combinations of 6-thioguanine and azaserine. Cancer Res 1958;18:938-942.
50. Hayes DM, Costa J, Moon JH et al. Combination therapy with thioguanine (NSC-752) and azaserine (NSC-742) formultiplemyeloma. CancerChemother Rep 1967;51:235-238.
51. Schroeder JM, Ansfield AR, Curreri AR et al. Toxicity and clinical trial of azaserine and 6-thioguanine in advanced solid malignant neoplasms. Br J Cancer 1964;13:449-458.
52. Allegra CJ, Drake JC, Jolivet J et al. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82: 4881-4885.
53. Tan CT, Wollner N, Trippett T et al. Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies. J Clin Oncol 1994;12:1955-1962.